Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00383019
Other study ID # A6641050
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 14, 2006
Est. completion date October 1, 2007

Study information

Verified date August 2021
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in efficacy and similarity of safety between Xalacom and Xalatan.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date October 1, 2007
Est. primary completion date October 1, 2007
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4 weeks or more. Exclusion Criteria: - History of no-response to timolol - History of trabeculectomy - History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months

Study Design


Intervention

Drug:
Xalatan
latanoprost 0.005%, one rop once daily in evening
Xalacom
latanoprost 0.005% adn timolol 0.5%, one drop, once daily

Locations

Country Name City State
Japan The University of Tokyo Hospital Bunkyo-ku Tokyo
Japan Tokyo Metropolitan Police Hospital Chiyoda Tokyo
Japan Ochanomizu Inoue Eye Clinic Chiyoda-ku Tokyo
Japan Hanasaki Eye Clinic Fuji Shizuoka
Japan Nakajima Eye Clinic Fuji Shizuoka
Japan Lumine Hatano Eye Clinic Fujisawa Kanagawa
Japan Hayashi Eye Hospital Fujuoka
Japan Hayashi Tennjin Eye Clinic Fukuoka
Japan Kato Eye Clinic Fukuoka
Japan Ohshima Hospital of Opthalmology Fukuoka
Japan Gifu University Hospital Gifu
Japan Keio Hachioji Matsumoto Eye Clinic Hachioji Tokyo
Japan Manabe Clinic Hamura Tokyo
Japan Hiroshima University Hospital Hiroshima
Japan Matsusura Eye Clinic Ichinomiya Aichi
Japan Nomura Eye Clinic Ichinomiya Aichi
Japan Tanino clinic Kamakura Kanagawa
Japan Kanazawa university hospital Kanazawa Ishikawa
Japan Tokyo Sugita Eye Center Katsushika-ku Tokyo
Japan Kiyosenomori Hospital Kiyose Tokyo
Japan Miyazaki Eye Clinic Koto-ku Tokyo
Japan Kobe University Hospital Koube Hyogo
Japan Hayashi Eye Clinic Kumagaya Saitama
Japan Takase Ganka Tairamachi Clinic Meguro Tokyo
Japan Ohashi Eye Clinic Meguro-ku Tokyo
Japan Yoshimura Eye & Internal Medical Clinic Mishima Shizuoka
Japan Miyata Eye Hospital Miyakonojo Miyazaki
Japan Kunitoshi Eye Clinic Musashino Tokyo
Japan Shimizu Eye Clinic Musashino Tokyo
Japan Suzuki Eye Clinic Nagoya Aichi
Japan TANABE Eye Clinic Nagoya Aichi
Japan Yasuma Eye Clinic Nagoya Aichi
Japan Mitsuhashi Eye Clinic Narashino Chiba
Japan Niigata University Medical and Dental Hospital Niigata
Japan Adachi Eye Clinic Osaka
Japan Nishi Eye Hospital Osaka
Japan Osaka Welfare Pension Hospital Osaka
Japan WAKABA Eye Clinic Ota-ku Tokyo
Japan Aoki eye clinic Sagamihara Kanagawa
Japan Fujita Eye Clinic Sapporo Kokkaido
Japan Kaimeido Eye Clinic Sapporo Hokkaido
Japan Ohtsuka Eye Clinic Sapporo Hokkaido
Japan Ohyachi Kyouritsu Eye Clinic Sapporo Hokkaido
Japan Sasamoto Eye Clinic Sapporo Hokkaido
Japan Seijo Clinic Setagaya Tokyo
Japan Yotsuya Shirato Ganka Shinjuku Tokyo
Japan Nanba Opthalmology Shizuoka
Japan Sugita Eye Hospital Sugita
Japan Muramatsu Ganka Clinic Susono Shizuoka
Japan Tachihi Bill clinic Tachikawa Tokyo
Japan Ueno Eye Clinic Taito-ku Tokyo
Japan Hiraoka Eye Clinic Tokorozawa Saitama
Japan Chihara Eye Clinic Uji Kyoto
Japan Kikuna Yuda Eye Clinic Yokohama Kanagawa

Sponsors (1)

Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of Intraocular Pressure (IOP) From Baseline to Week 8 Value at Week 8 minus value at baseline Baseline to Week 8
Secondary Change of IOP From Baseline to Week 4 Value at Week 4 minus value at baseline Baseline to Week 4
Secondary Number of Subjects With an IOP of <=15 mmHg at Week 8 Number of subjects who achieved IOP reduction to 15 mmHg or below at Week 8 Week 8
Secondary Number of Subjects With an IOP of <=16 mmHg at Week 8 Number of subjects who achieved IOP reduction to 16 mmHg or below at Week 8 Week 8
Secondary Percent Change of IOP From Baseline to Week 8 Value at Week 8 minus value at baseline was divided by baseline value, then multiplied by 100 Baseline to Week 8
Secondary Number of Subjects With an IOP of <=18 mmHg at Week 8 Number of subjects who achieved IOP reduction to 18 mmHg or below at Week 8 Week 8
Secondary Number of Subjects With an IOP Reduction of >=2 mmHg From Baseline to Week 8 Number of subjects whose IOP were reduced by 2 mmHg or more at Week 8 from baseline Baseline to Week 8
Secondary Number of Subjects With an IOP Reduction of >=3 mmHg From Baseline to Week 8 Number of subjects whose IOP were reduced by 3 mmHg or more at Week 8 from baseline Baseline to Week 8
Secondary Number of Subjects With an IOP of <=17 mmHg at Week 8 Number of subjects who achieved IOP reduction to 17 mmHg or below at Week 8 Week 8
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A